These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36270832)

  • 21. Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
    Fedier A; Maggi N; Tozzi A; Disler M; Coelho R; Jacob F; Heinzelmann-Schwarz V
    Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35642662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N
    Fukumoto T; Zhu H; Nacarelli T; Karakashev S; Fatkhutdinov N; Wu S; Liu P; Kossenkov AV; Showe LC; Jean S; Zhang L; Zhang R
    Cancer Res; 2019 Jun; 79(11):2812-2820. PubMed ID: 30967398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM
    Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
    Yanaihara N; Yoshino Y; Noguchi D; Tabata J; Takenaka M; Iida Y; Saito M; Yanagida S; Iwamoto M; Kiyokawa T; Chiba N; Okamoto A
    Gynecol Oncol; 2023 Jan; 168():83-91. PubMed ID: 36403366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired
    Nesic K; Kondrashova O; Hurley RM; McGehee CD; Vandenberg CJ; Ho GY; Lieschke E; Dall G; Bound N; Shield-Artin K; Radke M; Musafer A; Chai ZQ; Ghamsari MRE; Harrell MI; Kee D; Olesen I; McNally O; Traficante N; Australian Ovarian Cancer Study ; DeFazio A; Bowtell DDL; Swisher EM; Weroha SJ; Nones K; Waddell N; Kaufmann SH; Dobrovic A; Wakefield MJ; Scott CL
    Cancer Res; 2021 Sep; 81(18):4709-4722. PubMed ID: 34321239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary Somatic Mutations Restoring
    Kondrashova O; Nguyen M; Shield-Artin K; Tinker AV; Teng NNH; Harrell MI; Kuiper MJ; Ho GY; Barker H; Jasin M; Prakash R; Kass EM; Sullivan MR; Brunette GJ; Bernstein KA; Coleman RL; Floquet A; Friedlander M; Kichenadasse G; O'Malley DM; Oza A; Sun J; Robillard L; Maloney L; Bowtell D; Giordano H; Wakefield MJ; Kaufmann SH; Simmons AD; Harding TC; Raponi M; McNeish IA; Swisher EM; Lin KK; Scott CL;
    Cancer Discov; 2017 Sep; 7(9):984-998. PubMed ID: 28588062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    Wichmann C; Klotz DM; Zeiler HJ; Hilger RA; Grützmann K; Krüger A; Aust D; Wimberger P; Kuhlmann JD
    Gynecol Oncol; 2020 Dec; 159(3):850-859. PubMed ID: 32980128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
    Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer.
    Zhan Z; Zhang J; Liang H; Wang C; Hong L; Liu W
    Adv Sci (Weinh); 2024 Sep; 11(34):e2400140. PubMed ID: 38973255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
    Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer.
    McMellen A; Yamamoto TM; Qamar L; Sanders BE; Nguyen LL; Ortiz Chavez D; Bapat J; Berning A; Post MD; Johnson J; Behbakht K; Nurmemmedov E; Chuong EB; Bitler BG
    Mol Cancer Res; 2023 Jan; 21(1):3-13. PubMed ID: 36149636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
    Ali R; Alabdullah M; Alblihy A; Miligy I; Mesquita KA; Chan SY; Moseley P; Rakha EA; Madhusudan S
    Cancer Lett; 2020 Jan; 469():124-133. PubMed ID: 31669203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 35. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Waks AG; Cohen O; Kochupurakkal B; Kim D; Dunn CE; Buendia Buendia J; Wander S; Helvie K; Lloyd MR; Marini L; Hughes ME; Freeman SS; Ivy SP; Geradts J; Isakoff S; LoRusso P; Adalsteinsson VA; Tolaney SM; Matulonis U; Krop IE; D'Andrea AD; Winer EP; Lin NU; Shapiro GI; Wagle N
    Ann Oncol; 2020 May; 31(5):590-598. PubMed ID: 32245699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PARP inhibitors in ovarian cancer.
    Goldlust IS; Guidice E; Lee JM
    Semin Oncol; 2024; 51(1-2):45-57. PubMed ID: 38262776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring Molecular Drivers of PARPi Resistance in BRCA1-Deficient Ovarian Cancer: The Role of LY6E and Immunomodulation.
    Petta TB; Carlson J
    Int J Mol Sci; 2024 Sep; 25(19):. PubMed ID: 39408764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
    Pettitt SJ; Shao N; Zatreanu D; Frankum J; Bajrami I; Brough R; Krastev DB; Roumeliotis TI; Choudhary JS; Lorenz S; Rust A; de Bono JS; Yap TA; Tutt ANJ; Lord CJ
    Oncogene; 2023 Sep; 42(36):2701-2709. PubMed ID: 37491606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.